Barclays Research takes stock of the effects of Russia’s war with Ukraine in the 2022 Equity Gilt Study
13.7.2022 10:00:00 EEST | Business Wire | Press release
Barclays Research today released the 67th edition of the Equity Gilt Study (EGS), a flagship annual publication. Combining market-leading macro analysis with a unique multi-asset dataset spanning over 100 years, this year’s report takes stock of the effects of Russia’s war with Ukraine.
Barclays’ Research analysts survey the future of the European monetary union, arguing that Europe has often moved towards further integration during crises, and the recent past is no exception. The pandemic and the war in Ukraine have forced member states toward more fiscal and political co-operation. This includes a common diplomacy and defense policy, as well as a common energy policy.
Barclays Research argues that fears about the US dollar losing reserve currency status are greatly overstated. With the EMU still not fully integrated fiscally and politically and with the Chinese RMB only partially convertible, there are no good substitutes for the US dollar. Instead, large exporters might try to reduce their US current account surpluses by focusing more on regional trading blocs, in an attempt to diversify their foreign reserves.
In parallel, Barclays’ analysts note that the war is leading governments and corporations to re-examine the resilience of their supply chains and other economic linkages. That could lead to at least a partial reversal of the multi-decade trend of globalization. Already, our analysts see evidence of a “reshoring” of critical processes and infrastructure, and of multinational companies hiring closer to home.
Finally, Barclays’ analysts consider the implications for the macroeconomic environment, which, over the past three decades, has benefited from a period of “Great Moderation”, characterized by a relatively stable backdrop of growth, inflation, and monetary policy. We think this may be changing, with significant implications for macroeconomic stability.
“In this year’s Equity Gilt Study, Barclays’ analysts explore how the war in Ukraine, coming on the heels of the pandemic, will likely permanently re-shape the macro landscape,” says Ajay Rajadhyaksha, Global Chairman of Research at Barclays. “The Equity Gilt Study provides an indispensable tool to understand the themes and trends affecting global economies and markets for years to come.”
>>> Clients can gain access to the full EGS at Barclays Live
>>> To learn more about our Research offering and view recent insights, click here
Notes for Editors
Since 1956 Barclays’ Equity Gilt Study has provided uniquely rich data, analysis and commentary on long-term asset returns in the UK and US. Data for the UK goes back to 1899, while the US data, provided by the Center for Research in Security Prices at the University of Chicago, runs from 1925.
About Barclays
Barclays is a British universal bank. We are diversified by business, by different types of customer and client, and geography. Our businesses include consumer banking and payments operations around the world, as well as a top-tier, full service, global corporate and investment bank, all of which are supported by our service company which provides technology, operations and functional services across the Barclays Group. For further information about Barclays, please visit our website home.barclays.
About Barclays Corporate and Investment Bank
Barclays is a consumer and wholesale bank, supporting individuals and small businesses through our consumer banking services, and larger businesses and institutions through our corporate and investment banking services. Our Corporate and Investment Bank is comprised of the Investment Banking, International Corporate Banking, Global Markets and Research businesses; it provides money managers, financial institutions, governments, supranational organisations and corporate clients with services and advice for their funding, financing, strategic and risk management needs. For further information about Barclays Corporate and Investment Bank, please visit our website www.cib.barclays.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005235/en/
Contact information
Ann Thielke
212-526-1472 (US)
ann.thielke@barclays.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive Chairperson13.8.2026 17:05:00 EEST | Press release
Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced leadership expansion. Laura Shannon joins the organization as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson. This expansion of the senior leadership team is a recognition of a growing organization with global capabilities and continuing commitment to advancing treatments for patients with psychiatric and neurological disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813362140/en/ Laura Shannon joins Clinilabs as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson Ms. Shannon is a dynamic leader with more than 30 years of biopharma industry experience, known for her ability to build high-performing teams, forge strategic alliances, and drive
Resurgens Technology Partners Invests in Qarma to Advance the Future of Quality and Compliance13.8.2026 16:00:00 EEST | Press release
Resurgens Technology Partners (“Resurgens”), a software-focused private equity firm, today announced its partnership with Qarma, a leading global provider of AI-powered quality and compliance software for brands, retailers, and manufacturers managing complex, global supply chains. Qarma has built a platform that combines best-practice quality and compliance with hands-on execution where it matters most, on the factory floor. Qarma will continue to be led by its Co-founders, CEO Jacob Nedergaard and CTO Søren Mønsted. Founded in 2016, Qarma serves customers across industries, including furniture and home, apparel, consumer goods, and electronics. Its platform connects quality and compliance teams, sourcing professionals, suppliers, and inspectors. Over the past decade, Qarma has built one of the industry’s deepest operational quality platforms, combining best-practice workflows with software designed to work natively on factory floors worldwide. This unique operational foundation has ge
Tecnotree allekirjoitti 17,5 miljoonan Yhdysvaltain dollarin monivuotisen sopimuksen nykyisen teleoperaattoriasiakkaan kanssa Amerikan alueella13.8.2026 15:04:00 EEST | Tiedote
Tecnotree, joka on maailmanlaajuinen 5G- ja tekoälynatiivien digitaalisten BSS-ratkaisujen sekä teleoperaattoreille suunnattujen digitaalisen transformaation ratkaisujen toimittaja, ilmoitti eilen allekirjoittaneensa uuden monivuotisen ja usean alueen kattavan sopimuksen nykyisen teleoperaattoriasiakkaan kanssa Amerikan alueella. Sopimus kuvastaa Tecnotreen jatkuvaa painotusta pitkäaikaisten asiakassuhteiden laajentamiseen yhtiön 5G- ja tekoälynatiivien digitaalisten alustojen ja palvelujen avulla, jotka auttavat teleoperaattoreita uudistamaan liiketoimintaansa, nopeuttamaan palveluinnovaatioita ja parantamaan asiakaskokemusta. Tecnotree jatkaa operaattoreiden muuttuvien digitaalisen transformaation painopisteiden tukemista maailmanlaajuisesti. ”Amerikan alue on Tecnotreelle edelleen tärkeä markkina-alue, jolla yhtiö jatkaa teleoperaattoreiden tukemista ratkaisuilla, jotka yksinkertaistavat toimintaa, mahdollistavat liiketoiminnan ketteryyden ja luovat kestävää arvoa seuraavan sukupolv
Vantage Data Centers and Nebius Expand UK AI Infrastructure with First Deployment in South Wales AI Growth Zone13.8.2026 15:00:00 EEST | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, and Nebius (Nasdaq: NBIS), the AI cloud company, today announced an agreement to deploy high-density, NVIDIA-powered AI infrastructure at Vantage’s CWL1 campus in Newport, Wales. The deployment represents the first announced commercial capacity commitment in the South Wales AI Growth Zone and will support growing UK demand for domestic AI compute capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813253918/en/ CWL13 data center at Vantage’s Newport, Wales, campus. Under the agreement, Nebius will lease high-density capacity at CWL1 to support AI training, inference, agentic AI and enterprise AI workloads, serving enterprises, researchers, startups and public sector organizations seeking access to advanced AI infrastructure. This capacity is part of Nebius’ broader UK expansion and commitment to scale domestic AI compute capacity. In
SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results13.8.2026 13:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the second quarter of fiscal year 2026 (the three months ended June 30, 2026) and the first half of fiscal year 2026 (the six months ended June 30, 2026). Second Quarter 2026 Financial Highlights Total revenues were $49 million, an increase of 13% year-over-year. Net income attributable to SBC Medical was $11 million, an increase of 335% year-over-year. Net income margin was 22%, an increase of 16 percentage points year-over-year. Adjusted EBITDA1 was $20 million, an increase of 32% year-over-year. Adjusted EBITDA margin1 was 41%, an increase of 6 percentage points year-over-year. Basic EPS was $0.10 for the three months ended June 30, 2026, an increase of 400% year-over-year. The Company believ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
